T-knife GmbH, which is developing adoptive T cell therapies, has appointed Thomas Soloway as chief executive, and Camille Landis as chief business officer and chief financial officer, ahead of its transition from a discovery to a clinical-stage company. Concurrently, Elisa Kieback, the company’s founding CEO, has assumed the role of chief technical officer.
Mr Soloway joins T-knife from Audentes Therapeutics where he was chief operating officer for the genetic medicines company. Prior to this, he was CFO of Ascendis Pharma A/S, a developer of drugs for rare endocrinology diseases.
Ms Landis joins T-knife from Unity Biotechnology Inc, where she was head of corporate development. The company has a pipeline of candidate products for age-related diseases. Before that, she was chief business officer at Eidos Therapeutics Inc.
T-knife announced the appointments on 19 January 2021.
Copyright 2021 Evernow Publishing Ltd